SOP 09-301 requires analytical balances to be placed on a vibration proof surface.
Inspection Record
Qingdao Kangyuan Pharmaceutical Co., LTD — FDA 483 Findings
Inspectors Jose R. HernandezThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
The BPR does not document the duration of the, _—step of the 4) 4 during production; for example, at | | ?
There was no identification, calibration record, or usage log on a scale found in the raw material weighing and dispensing room.
The pw step requires the use of oa i apparatus).
The contract laboratory performs the residual solvent test for detectinga@ in the finished product.
There was no study protocol to for developing an impurity profile on the product nor there was an impurity profile on@@ for review.
A record as of the US FDA document published on 2026-11-13. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.